Last reviewed · How we verify
Mesenchymal stem cells low-dose group
At a glance
| Generic name | Mesenchymal stem cells low-dose group |
|---|---|
| Also known as | Adipose tissue derived mesenchymal stem cells |
| Sponsor | Shanghai AbelZeta Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture (PHASE1)
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) (PHASE2)
- Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS (PHASE1, PHASE2)
- The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency (PHASE2)
- The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis (PHASE2)
- Phase 1 Clinical Trial of CordSTEM-ST (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesenchymal stem cells low-dose group CI brief — competitive landscape report
- Mesenchymal stem cells low-dose group updates RSS · CI watch RSS
- Shanghai AbelZeta Ltd. portfolio CI